Uso de posaconazol en niños: experiencia en un hospital pediátrico de alta complejidad

Abstract

There is limited information on the use of posaconazole in children. This retrospective and descriptive study was conducted to evaluate the clinical, microbiological characteristics and evolution of patients treated with posaconazole between August 2010 and March 2017. We included 16 children. Median age: 161 months (interquartile range -IQR- 69-173 m). All had underlying disease and a proven invasive fungal infection. The most frequent isolated were Mucor spp. and Aspergillus spp. The mean posaconazole dose was 600 mg/day (400-800 mg/day) and the median duration of treatment was 223 days (IQR 48-632). Ten patients had adverse effects, but only one required suspension of the antifungal treatment due to hydroelectrolytic disorders.

Prophylaxis for invasive fungal infection in pediatric patients with allogeneic hematopoietic stem cell transplantation

“…Antifungal prophylaxis has reduced the number of fungal infections in patients who have undergone allogeneic hematopoietic stem cell transplantation (AHSCT) [ 9 ]. Different regimens are used in pediatric patients, including fluconazole [ 10 ], voriconazole [ 11 , 12 ], itraconazole [ 13 ], caspofungin [ 14 ], and posaconazole [ 15 ]. Voriconazole has shown an acceptable tolerance profile, manageable and transient adverse events, and adequate antifungal coverage against filamentous fungi [ 16 ].…”